Inovio Pharmaceuticals, Inc. (INO) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and welcome to the Inovio fourth quarter and year end 2023 financial results conference calls. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Wednesday, March 6th, 2024. I would now like to turn the conference over to Thomas Hong, Manager of Investor Relations. Please go ahead. Good afternoon, and thank you for joining the Inovio 2023 Fourth Quarter and Full Year Financial Results Conference Call. Joining me on today's call are Dr. Jackie Shea, President and Chief Executive Officer, Dr. Michael Sumner, Chief Medical Officer, Mark Twyman, Chief Commercial Officer, and Peter Keyes, Chief Financial Officer. Today's call will review our corporate and financial information for the quarter and full year ended December 31st, 2023, as well as provide a general business update. Following prepared remarks, we will conduct a question and answer segment. During the call, we will be making forward-looking statements regarding future events and the future performance of the company. These events relate to our business plans to develop Inovio's DNA medicines platform, which include clinical and regulatory developments and timing of clinical data readouts, along with capital resources and strategic matters. All of these statements are based on the beliefs and expectations of management as of today. Actual events or results could differ materially. We refer you to the documents we file from time to time with the SEC which under the heading Risk Factors, identify important factors that could cause actual results to differ materially fro...